Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMEERA-2: Phase 1 amcenestrant monotherapy in Japanese postmenopausal women with ER-positive/HER2-negative advanced breast cancer
jRCT2080224576Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amcenestrant in breast cancer (2 arms), sponsored by Sanofi. Started Feb 2019; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224576.